Approval · Notice of Compliance 30650 · 2023
3TC: Notice of Compliance 30650
Issued May 3, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30650
- Date
- May 3, 2023
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph (PM) to remove a warning related to the risk of sexual Human Immunodeficiency Virus-1 (HIV-1) transmission and to remove a recommendation that 3TC therapy should be initiated by a physician experienced in the management of HIV infection
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| 3TC | Not yet assigned | — |
Medicinal ingredients
- LAMIVUDINE 150 MG per TAB
- LAMIVUDINE 300 MG per TAB
- LAMIVUDINE 10 MG per ML